Perspective Therapeutics Appoints New Chief Medical Officer
Ticker: CATX · Form: 8-K · Filed: Jan 6, 2025 · CIK: 728387
Sentiment: neutral
Topics: executive-appointment, personnel
TL;DR
Perspective Therapeutics just hired a new CMO, Dr. Roth, from Luminary Therapeutics. Big move for their oncology pipeline.
AI Summary
Perspective Therapeutics, Inc. announced on January 2, 2025, the appointment of Dr. Jonathan M. Roth as Chief Medical Officer. Dr. Roth previously served as Chief Medical Officer at Luminary Therapeutics, Inc. and brings extensive experience in oncology drug development.
Why It Matters
The appointment of a new Chief Medical Officer with oncology experience is crucial for advancing the company's drug development pipeline and potentially bringing new treatments to market.
Risk Assessment
Risk Level: medium — The appointment of a key executive like a CMO can significantly impact a company's strategic direction and execution, introducing both opportunities and potential risks.
Key Players & Entities
- Perspective Therapeutics, Inc. (company) — Registrant
- Dr. Jonathan M. Roth (person) — Appointed Chief Medical Officer
- Luminary Therapeutics, Inc. (company) — Dr. Roth's previous employer
FAQ
What is the effective date of Dr. Jonathan M. Roth's appointment as Chief Medical Officer?
The filing does not explicitly state the effective date of Dr. Roth's appointment, but the report is dated January 2, 2025, indicating the event occurred around this time.
What was Dr. Roth's previous role before joining Perspective Therapeutics?
Dr. Roth previously served as Chief Medical Officer at Luminary Therapeutics, Inc.
What is Perspective Therapeutics, Inc.'s primary industry?
Perspective Therapeutics, Inc. is in the Surgical & Medical Instruments & Apparatus industry, SIC code 3841.
What is the Commission File Number for Perspective Therapeutics, Inc.?
The Commission File Number for Perspective Therapeutics, Inc. is 001-33407.
Has Perspective Therapeutics, Inc. undergone any previous name changes?
Yes, Perspective Therapeutics, Inc. was formerly known as Isoray, Inc. (name change effective 20181231) and IsoRay, Inc. (name change effective 20050805), and prior to that, CENTURY PARK PICTURES CORP (name change effective 19920703).
Filing Stats: 1,794 words · 7 min read · ~6 pages · Grade level 12 · Accepted 2025-01-06 08:05:24
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CATX NYSE American LLC
- $500,000 — m will receive an annual base salary of $500,000 and will be eligible for an annual bonu
- $80,000 — one-time signing bonus in the amount of $80,000 (the "Signing Bonus"). If Mr. Graham vo
Filing Documents
- catx-20250102.htm (8-K) — 55KB
- catx-ex99_1.htm (EX-99.1) — 21KB
- img236230851_0.jpg (GRAPHIC) — 22KB
- 0000950170-25-001712.txt ( ) — 225KB
- catx-20250102.xsd (EX-101.SCH) — 23KB
- catx-20250102_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 6, 2025, the Company issued a press release announcing the leadership transition described in Item 5.02 of this Form 8-K and related matters. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01. The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company's filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated January 6, 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PERSPECTIVE THERAPEUTICS, INC. Date: January 6, 2025 By: /s/ Johan (Thijs) Spoor Johan (Thijs) Spoor Chief Executive Officer